接受生物制剂治疗的类风湿关节炎患者金黄色葡萄球菌鼻腔携带率增加
该前瞻性研究于2017年4月至2018年5月连续入组接受生物制剂(±DMARDs)的类风湿关节炎患者、接受非生物制剂DMARDs的类风湿关节炎患者及骨关节炎患者,比较金黄色葡萄球菌鼻腔携带率。接受生物制剂的类风湿关节炎患者携带率为37%,高于单用DMARDs的类风湿关节炎患者(24%)和骨关节炎患者(20%)(总体P=0.01);控制糖皮质激素、抗生素使用、近期住院和糖尿病后,接受生物制剂的类风湿关节炎患者鼻腔定植风险仍显著增加(OR 1.80,95%CI 1.00-3.22,P=0.047)。
要点
- 接受生物制剂的类风湿关节炎患者金黄色葡萄球菌鼻腔携带率为37%,高于单用DMARDs者(24%)和骨关节炎患者(20%)(总体P=0.01)。
- 控制糖皮质激素、抗生素、近期住院和糖尿病后,接受生物制剂的类风湿关节炎患者鼻腔定植风险增加(OR 1.80,95%CI 1.00-3.22,P=0.047)。
- 作者认为鼻腔金黄色葡萄球菌携带增加手术部位感染风险,这一可改变的危险因素应在全关节置换术前处理。
核心结论
- 接受生物制剂的类风湿关节炎患者较未接受生物制剂的类风湿关节炎患者和骨关节炎患者,金黄色葡萄球菌定植风险增加。
- 作者认为鼻腔金黄色葡萄球菌携带增加手术部位感染风险,这一可改变的危险因素应在全关节置换术前处理。
研究设计与样本
- 前瞻性连续入组2017年4月至2018年5月接受生物制剂(±DMARDs)的类风湿关节炎患者、接受非生物制剂DMARDs的类风湿关节炎患者及骨关节炎患者。
- 每组需123例患者以显示携带率差异。
- 患者接受鼻腔拭子采样并回答问卷以识别其他危险因素,金黄色葡萄球菌阳性拭子进一步行spa分型。
- 采用逻辑回归控制已知危险因素后评估组间金黄色葡萄球菌定植的关联。
主要发现
- 接受生物制剂的类风湿关节炎患者(其中70%使用DMARDs)金黄色葡萄球菌定植率为37%,高于单用DMARDs的类风湿关节炎患者(24%)和骨关节炎患者(20%)(总体P=0.01)。
- 控制糖皮质激素、抗生素使用、近期住院和糖尿病后,接受生物制剂的类风湿关节炎患者鼻腔金黄色葡萄球菌定植风险显著增加(OR 1.80,95%CI 1.00-3.22,P=0.047)。
临床怎么用
- 作者认为鼻腔金黄色葡萄球菌携带增加手术部位感染风险,这一可改变的危险因素应在全关节置换术前处理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis patients are at increased risk for periprosthetic joint infection after arthroplasty. The reason is multifactorial. Nasal colonization with Staphylococcus aureus is a modifiable risk factor; carriage rates in RA patients are unknown. The goal of this study is to determine the S aureus nasal carriage rates of RA patients on biologics, RA patients on traditional disease-modifying anti-rheumatic drugs (DMARDs), and osteoarthritis. METHODS: Consecutive patients with RA on biologics (±DMARDs), RA on non-biologic DMARDs, or OA were prospectively enrolled from April 2017 to May 2018. One hundred twenty-three patients were determined necessary per group to show a difference in carriage rates. Patients underwent a nasal swab and answered questions to identify additional risk factors. S aureus positive swabs were further categorized using spa typing. Logistic regression evaluated the association with S aureus colonization between the groups after controlling for known risk factors. RESULTS: RA patients on biologics, 70% of whom were on DMARDs, had statistically significant increase in S aureus colonization (37%) compared to RA on DMARDs alone (24%), or OA (20%) (P = .01 overall). After controlling for glucocorticoids, antibiotic use, recent hospitalization, and diabetes, RA on biologics had a significant increased risk of S aureus nasal colonization (Odds ratio 1.80, 95% confidence interval 1.00-3.22, P = .047). CONCLUSION: S aureus colonization risk was increased for RA on biologics compared to RA not on biologics and OA. Nasal S aureus carriage increases the risk of surgical site infection; this modifiable risk factor should be addressed prior to total joint arthroplasty for this higher risk patient group.
引用
- Goodman SM, Nocon AA, Selemon NA, et al. Increased Staphylococcus aureus Nasal Carriage Rates in Rheumatoid Arthritis Patients on Biologic Therapy. J Arthroplasty. 2019. PMID: 30733073. doi:10.1016/j.arth.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。